🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Insys founder faces stiff prison sentence, $100 million-plus in forfeiture

Published 01/23/2020, 09:20 AM
© Reuters. FILE PHOTO: John Kapoor, the billionaire founder of Insys Therapeutics Inc., leaves the federal courthouse in Boston
COST
-
INSYQ
-

By Tim McLaughlin

BOSTON (Reuters) - John Kapoor, the founder of Insys Therapeutics Inc (PK:INSYQ), on Thursday could be sentenced to several years in prison and ordered to forfeit up to $113 million for his role in a bribery and fraud scheme that contributed to the U.S. opioid crisis.

U.S. Attorney in Boston Andrew Lelling has asked the court to sentence Kapoor to 15 years in prison and seek more than $113 million from him.

U.S. District Court Judge Allison D. Burroughs already has sentenced four other former Insys executives, but her punishments have been less than three years in prison on government recommendations of more than 10 years.

Kapoor is scheduled to become the highest-ranking pharmaceutical executive to be sentenced in a case linked to the opioid crisis.

Last year, a federal jury in Boston found Kapoor guilty of racketeering conspiracy in a scheme that involved bribing doctors to prescribe the company's fentanyl-based painkiller, Subsys. The scheme also defrauded insurers into paying for the drug.

From 1999 to 2017, some 400,000 people died from overdoses involving an opioid, including prescription and illicit drugs, according to the U.S. Centers for Disease Control and Prevention.

"Kapoor was the company's founder ... who did not hesitate to use the authority of his financial position to dictate the criminal strategies employed by Insys," Lelling's office wrote in a filing with the court.

"He was the principal leader, who personally approved, and thereafter enforced, the corrupt strategies employed throughout the conspiracy. This crime would not have happened, could not have happened, without John Kapoor," the filing said.

Kapoor, who served as the Chandler, Arizona-based drugmaker's chairman and later chief executive, lost nearly $80 million through his association with Insys, according to court filings by his defense team. Insys filed for bankruptcy protection in 2019.

"He does not expect anyone to feel sorry for him for that loss, and he is of course facing other sentencing consequences that cannot be expressed in monetary terms," his defense team said in filings with the court.

© Reuters. FILE PHOTO: John Kapoor, the billionaire founder of Insys Therapeutics Inc., leaves the federal courthouse in Boston

In a letter to the judge, Mary Gauwitz, one of many friends who wrote in support of Kapoor, described him as a man who enjoys a $4.99 rotisserie chicken from Costco (NASDAQ:COST). He also made sure everyone at the Editha House in Phoenix, which provides housing and assistance to cancer patients, received rotisserie chickens, too, if they wanted one, Gauwitz wrote.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.